Marine Compounds Show Promise Against Neuroinflammation Driving Alzheimer's and Parkinson's
A comprehensive review examines how marine-derived bioactives like omega-3s, astaxanthin, and polysaccharides may combat chronic neuroinflammation underlying major neurodegenerative diseases.
Summary
This review from Italian researchers explores how chronic neuroinflammation drives Alzheimer's disease, Parkinson's disease, multiple sclerosis, and ALS — and how bioactive compounds sourced from marine organisms may help counter these processes. The authors detail the three-phase neuroinflammatory cycle (onset, resolution, adaptive homeostasis) and explain how its failure produces persistent low-grade inflammation that damages neurons. They then survey marine-derived candidates including omega-3 fatty acids (EPA/DHA), astaxanthin, marine polysaccharides, peptides, and polyphenols, reviewing preclinical and emerging clinical evidence for their ability to suppress NF-κB signaling, reduce ROS production, inhibit microglial overactivation, and promote pro-resolving mediators — mechanisms directly relevant to slowing neurodegeneration.
Detailed Summary
Neurodegenerative diseases (NDDs) including Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) collectively represent one of the most pressing unmet medical needs globally. This 2025 review published in Marine Drugs by Favari and Parolini synthesizes current understanding of chronic neuroinflammation as a shared pathological driver across these conditions, and evaluates the therapeutic potential of marine-derived bioactive compounds. The authors argue that the nervous and immune systems form a deeply integrated bidirectional network — the so-called 'neuroimmune connectome' — and that disruption of normal inflammatory resolution is central to NDD pathogenesis.
The review carefully maps the three-phase neuroinflammatory program: an onset phase triggered by pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) sensed by pattern recognition receptors (PRRs) including TLRs, NLRs, CLRs, and RLRs; a resolution phase involving anti-inflammatory cytokines and specialized pro-resolving mediators (SPMs); and adaptive homeostasis. When resolution fails, chronic low-grade neuroinflammation ensues, with persistent NF-κB and MAPK activation driving TNF, IL-1β, IL-6, ROS, and NO production — all documented in AD, PD, MS, and ALS brain tissue. In AD specifically, amyloid-beta plaques activate microglia via TLRs, RAGE, and NLRs, creating a vicious cycle where inflammatory mediators increase Abeta production while impairing its clearance, particularly in apoE4 carriers. In PD, misfolded alpha-synuclein aggregates activate TLR signaling and NADPH oxidase in microglia, releasing cytotoxic ROS and NO that accelerate dopaminergic neuron loss in the substantia nigra.
Against this mechanistic backdrop, the authors survey marine bioactives with documented anti-neuroinflammatory activity. Omega-3 polyunsaturated fatty acids (EPA and DHA) are the most extensively studied, with DHA constituting approximately 30–40% of total fatty acids in neuronal membranes. These lipids serve as precursors to SPMs — resolvins, protectins, and maresins — that actively terminate inflammatory cascades. Marine polysaccharides such as fucoidan (from brown algae) and carrageenan derivatives have demonstrated inhibition of microglial NF-κB activation and reduction of pro-inflammatory cytokine release in cell and animal models. Astaxanthin, a ketocarotenoid abundant in krill, salmon, and microalgae, is highlighted as a particularly potent antioxidant (estimated 10-fold stronger than other carotenoids) capable of crossing the blood-brain barrier, suppressing NF-κB, and reducing oxidative damage in neuronal tissue.
Marine peptides derived from fish collagen hydrolysates and shellfish proteins have shown neuroprotective effects in rodent models of AD and PD, partly through inhibition of acetylcholinesterase and BACE-1 (beta-secretase). Marine polyphenols, including phlorotannins from brown algae, exhibit anti-amyloidogenic properties by interfering with Abeta aggregation and tau hyperphosphorylation pathways. The review also notes that these compounds modulate the gut-brain axis, with marine prebiotics influencing microbiome composition in ways that reduce systemic and neuroinflammatory tone — a mechanism increasingly recognized as relevant to NDD progression.
The authors acknowledge that most evidence remains preclinical, with robust human clinical trial data still limited. Bioavailability challenges, particularly for polyphenols and large polysaccharides, remain significant barriers to translation. Nevertheless, the convergence of anti-inflammatory, antioxidant, and pro-resolving mechanisms across multiple marine compound classes presents a compelling rationale for further investigation, both as preventive dietary strategies and as adjuncts to pharmacological treatment of established NDDs.
Key Findings
- Chronic low-grade neuroinflammation — driven by failed resolution of the three-phase inflammatory program — is identified as a shared pathological mechanism across AD, PD, MS, and ALS
- Amyloid-beta plaques activate microglia via TLRs, RAGE, and NLRs, triggering NF-κB-mediated TNF, IL-1β, IL-6, ROS, and NO release that creates a self-amplifying neurotoxic cycle in AD
- Alpha-synuclein aggregates in PD activate TLR signaling and NADPH oxidase in microglia, producing cytotoxic ROS and NO that accelerate dopaminergic neuron loss in the substantia nigra
- DHA constitutes approximately 30–40% of total fatty acids in neuronal membranes and serves as a precursor to specialized pro-resolving mediators (resolvins, protectins, maresins) that actively terminate neuroinflammatory cascades
- Astaxanthin is estimated to be approximately 10-fold more potent as an antioxidant than other carotenoids, crosses the blood-brain barrier, and suppresses NF-κB activation in neuronal tissue
- Marine polysaccharides (fucoidan, carrageenan derivatives) and phlorotannins from brown algae demonstrate inhibition of microglial NF-κB activation and anti-amyloidogenic properties in preclinical models
- Genetic contributors are identifiable in approximately 15% of PD cases, with over 200 PD-associated genes identified, many interacting with aging and environmental factors including diet
Methodology
This is a narrative review article, not a primary clinical trial or meta-analysis. The authors systematically surveyed published literature on neuroinflammatory mechanisms in AD, PD, MS, and ALS, and on marine-derived bioactive compounds with anti-neuroinflammatory properties. Evidence cited spans in vitro cell studies, rodent models, and available human observational and clinical trial data. No formal systematic review protocol, PRISMA methodology, or quantitative meta-analysis was applied; the review reflects the authors' expert synthesis of the field.
Study Limitations
The review is narrative rather than systematic, meaning selection bias in cited studies cannot be excluded and effect sizes across studies are not formally pooled or compared. The majority of mechanistic evidence for marine bioactives comes from preclinical (cell and animal) models, with limited robust human RCT data, and bioavailability of several compounds (particularly polyphenols and large polysaccharides) in the CNS remains poorly characterized. The authors declare no external funding and no conflicts of interest.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.